Sold as Pixclara. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Floretyrosine F-18 (sold as Pixclara), first approved Sep 11, 2026, with 0 new uses approved and 1 published complete response letter.
| Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 TrialGlioblastoma, IDH-Wildtype · Mayo Clinic | Phase 3 | Not yet recruiting | Nov 13, 2026 |
| [18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain MetastasesBrain Metastasis, Radiation Necrosis · Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | Not yet recruiting | Nov 12, 2026 |
| Letter | Product | Now |
|---|---|---|
| Apr 25, 2025 | NDA 218592Clinical/Statistical, Product Quality | Unapproved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA